Key result
Semi-rapid pacing-assisted Evolut FX deployment linked to ~5-minute shorter device time vs conventional deployment.
Why the study?
As TAVI expands, improving deployment efficiency is increasingly important, motivating evaluation of the procedural efficiency and early safety of a semi-rapid pacing-assisted deployment workflow for transfemoral Evolut FX TAVI.
Does a semi-rapid pacing-assisted deployment workflow (alternating 100 bpm and 150 bpm pacing) reduce device time and maintain early safety compared to conventional 100 bpm deployment in patients with severe aortic stenosis undergoing transfemoral Evolut FX TAVI?
Observational (n=101)
Open-label
No
Does a semi-rapid pacing-assisted deployment workflow (alternating 100 bpm and 150 bpm pacing) reduce device time and maintain early safety compared to conventional 100 bpm deployment in patients with severe aortic stenosis undergoing transfemoral Evolut FX TAVI?
A semi-rapid pacing-assisted deployment workflow alternating between 100 bpm and 150 bpm during transfemoral Evolut FX TAVI reduced median device deployment time by 5 minutes without compromising early in-hospital safety or valve performance.
Answers are grounded in this paper and cite their sources.
May expedite Evolut FX deployment without early safety signals; hypothesis-generating and requires randomized confirmation before practice change.
Background: As transcatheter aortic valve implantation (TAVI) expands, improving deployment efficiency is increasingly important. We developed and implemented a semi-rapid pacing-assisted deployment workflow for the Evolut platform. Aims: We sought to evaluate the procedural efficiency and early safety of this workflow for transfemoral (TF) Evolut FX TAVI. Methods: In a single-centre registry, we performed a retrospective before-and-after analysis of consecutive TF Evolut FX procedures: semi-rapid deployment (n=48) versus conventional deployment (n=53). Device time was defined as the interval from initial advancement of the delivery system to final release of the Evolut FX valve. Prolonged device time was defined as >14 minutes (>75th percentile), and determinants were assessed using Firth's penalised logistic regression. Results: The device time was shorter with semi-rapid deployment (9.0 [interquartile range [IQR] 6.0-13.0] minutes vs 14.0 [IQR 11.0-16.0] minutes; p<0.001), while operation and procedure times were similar (p=0.13 and p=0.16, respectively). The mean recapture count was higher in the semi-rapid group (0.85±1.09 vs 0.53±0.70; p=0.08), and contrast volume was higher (32.0 [IQR 25.0-42.0] mL vs 25.0 [IQR 15.0-33.0] mL; p=0.008). Paravalvular leak >=mild (31.2% vs 32.1%; p=1.0) and in-hospital pacemaker implantation (2.1% vs 7.5%; p=0.37) did not differ significantly between the groups. In multivariable analysis, recapture predicted a prolonged device time (adjusted odds ratio [OR] 4.74, 95% confidence interval [CI]: 1.75-14.19; p=0.002), whereas the semi-rapid workflow predicted a reduced device time (adjusted OR 0.10, 95% CI: 0.01-0.66; p=0.015). Conclusions: Semi-rapid pacing-assisted Evolut FX deployment selectively reduced device time without compromising early in-hospital safety outcomes. Deployment efficiency represents a practical procedural target for workflow refinement in self-expanding TAVI.
No takes yet. Share an insight, caveat, or question.
Doi et al. (2026) conducted an observational in Severe aortic stenosis undergoing transfemoral transcatheter aortic valve implantation (TAVI) (n=101). Semi-rapid pacing-assisted deployment workflow (alternating 100 and 150 bpm) vs. Conventional stepwise deployment workflow (100 bpm pacing) was evaluated on Device time (interval in minutes from initial advancement of the delivery system to final release of the Evolut FX valve) (OR 0.10, 95% CI 0.01-0.66, p=<0.001). Semi-rapid pacing-assisted Evolut FX deployment shortened median device time compared to conventional deployment without compromising early in-hospital safety.
Synapse has enriched 10 related papers. Consider them for comparative context: